Article
Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.
Clinica chimica acta; international journal of clinical chemistry - 10 Jun 2014
Santos Izabela R, Fernandes Ana P, Carvalho Maria G, Sousa Marinez O, Ferreira Cláudia N, Gomes Karina B
Abstract excerpt
BACKGROUND: Dyslipidemia, a metabolic alteration that affects lipoprotein levels, is considered a major risk factor for atherosclerosis and its complications. Dyslipidemia also affects the hemostatic system, especially impairing fibrinolysis, and increased levels of thrombin-activatable fibrinolysis inhibitor (TAFI) have been associated with cardiovascular events. OBJECTIVES AND METHODS: This study evaluated the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
